A new polymorphic probe on chromosome 3p: lambda LIB05-24 (D3S623)

Autor: Latif F, Gm, Glenn, Hiltrud Brauch, Delisio J, Hampsch K, Ml, Orcutt, Zbar B, Mi, Lerman

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c8f8b2462cfe85439663391772b64375
https://pubmed.ncbi.nlm.nih.gov/2017383

A new polymorphic probe on chromosome 3p: lambda LIB43-55' (D3S728)

Autor: Latif F, Gm, Glenn, Tory K, Hiltrud Brauch, Delisio J, Hampsch K, Ml, Orcutt, Zbar B, Mi, Lerman

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1aab56546b314ba60c7637f4ce3cb3ab
http://europepmc.org/abstract/med/1708132

Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M ^TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.

Autor: Shinde V; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Lombard Koen A; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Hoosain Z; Research and Development, Josha Research Centre, Bloemfontein, Free State, South Africa., Archary M; Paediatric Infectious Diseases Unit, University of KwaZulu-Natal, Durban, South Africa., Bhorat Q; Research and Development, Soweto Clinical Trials Centre, Johannesburg, South Africa., Fairlie L; Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Lalloo U; Respiratory and Critical Care Unit, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa., Masilela MSL; Research and Development, Setshaba Research Centre, Tshwane, South Africa., Moodley D; Department of Obstetrics and Gynaecology, University of KwaZulu-Natal, Durban, South Africa., Hanley S; Centre for the AIDS Programme of Research in South Africa (CAPRISA), and Department of Family Medicine, University of KwaZulu-Natal, Durban, South Africa., Fouche LF; Research and Development, Limpopo Clinical Research Initiative, Thabazimbi, South Africa., Louw C; Research and Development, Madibeng Centre for Research, Brits, South Africa.; Faculty of Health Sciences, Department of Family Medicine, University of Pretoria, Pretoria, South Africa., Tameris M; South African TB Vaccine Initiative, University of Cape Town, Cape Town, South Africa., Singh N; South African Medical Research Council, HIV and other Infectious Diseases Research Unit (HIDRU) and, Health Systems Research Unit, Durban, South Africa., Goga A; South African Medical Research Council, HIV and other Infectious Diseases Research Unit (HIDRU) and, Health Systems Research Unit, Durban, South Africa., Dheda K; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, University of Cape Town, Cape Town, South Africa., Grobbelaar C; Aurum Institute, University of Pretoria, Pretoria, South Africa., Joseph N; Research and Development, PEERMED Clinical Trial Centre, Kempton Park, South Africa., Lombaard JJ; Research and Development, Josha Research Centre, Bloemfontein, Free State, South Africa., Mngqibisa R; Paediatric Infectious Diseases Unit, University of KwaZulu-Natal, Durban, South Africa., Bhorat AE; Research and Development, Soweto Clinical Trials Centre, Johannesburg, South Africa., Benadé G; Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Lalloo N; Respiratory and Critical Care Unit, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa., Pitsi A; Research and Development, Setshaba Research Centre, Tshwane, South Africa., Vollgraaff PL; Research and Development, Limpopo Clinical Research Initiative, Thabazimbi, South Africa., Luabeya A; South African TB Vaccine Initiative, University of Cape Town, Cape Town, South Africa., Esmail A; Centre for Lung Infection and Immunity, Division of Pulmonology, Department of Medicine and UCT Lung Institute, University of Cape Town, Cape Town, South Africa., Petrick FG; Research and Development, MERC Research, Middelburg, South Africa., Oommen Jose A; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Foulkes S; Research and Development, Josha Research Centre, Bloemfontein, Free State, South Africa., Ahmed K; Research and Development, Setshaba Research Centre, Tshwane, South Africa.; Faculty of Health Sciences, Department of Microbiology, University of Pretoria, Pretoria, South Africa., Thombrayil A; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Kalonji D; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; South African Medical Research Council, HIV and other Infectious Diseases Research Unit (HIDRU) and, Health Systems Research Unit, Durban, South Africa., Cloney-Clark S; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Zhu M; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Bennett C; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Albert G; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Marcheschi A; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Plested JS; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Neal S; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Chau G; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Cho I; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Fries L; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Glenn GM; Research and Development, Novavax, Inc, Gaithersburg, MD, USA., Madhi SA; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2425147. Date of Electronic Publication: 2024 Dec 12.

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.

Autor: Bennett C; Novavax, Gaithersburg, MD, USA. Electronic address: cbennett@novavax.com., Woo W; Novavax, Gaithersburg, MD, USA., Bloch M; Holdsworth House Medical Practice, Sydney, NSW, Australia; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Cheung K; Emeritus Research, Camberwell, VIC, Australia., Griffin P; Mater Health, Mater Medical Centre, South Brisbane, QLD, Australia; The University of Queensland, Mater Clinical Unit, Brisbane St Lucia, QLD, Australia., Mohan R; Paratus Clinical Research Western Sydney, Blacktown, NSW, Australia., Deshmukh S; Griffith University, Southport, QLD, Australia., Arya M; Australian Clinical Research Network, Maroubra, NSW, Australia., Cumming O; Novatrials, Kotara, NSW, Australia., Neville AM; AusTrials, Taringa, QLD, Australia., McCallum Pardey TG; Novatrials, Kotara, NSW, Australia., Plested JS; Novavax, Gaithersburg, MD, USA., Cloney-Clark S; Novavax, Gaithersburg, MD, USA., Zhu M; Novavax, Gaithersburg, MD, USA., Kalkeri R; Novavax, Gaithersburg, MD, USA., Patel N; Novavax, Gaithersburg, MD, USA., Marcheschi A; Novavax, Gaithersburg, MD, USA., Swan J; Novavax, Gaithersburg, MD, USA., Smith G; Novavax, Gaithersburg, MD, USA., Cho I; Novavax, Gaithersburg, MD, USA., Glenn GM; Novavax, Gaithersburg, MD, USA., Walker R; Novavax, Gaithersburg, MD, USA., Mallory RM; Novavax, Gaithersburg, MD, USA.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Jun; Vol. 24 (6), pp. 581-593. Date of Electronic Publication: 2024 Mar 06.

Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.

Autor: Fries L; Clinical Development., Formica N; Clinical Development., Mallory RM; Clinical Development., Zhou H; Discovery., Plested JS; Clinical Immunology, Novavax, Inc, Gaithersburg, Maryland., Kalkeri R; Clinical Immunology, Novavax, Inc, Gaithersburg, Maryland., Moldovan I; Cellular Technology Ltd, Shaker Heights, Ohio., Patel N; Discovery., Albert G; Medical Writing., Robinson M; Clinical Operations., Cho I; Biostatistics, Novavax, Inc, Gaithersburg, Maryland., Chau G; Biostatistics, Novavax, Inc, Gaithersburg, Maryland., Dubovsky F; Clinical Development., Glenn GM; Discovery.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2023 Sep 15; Vol. 228 (6), pp. 734-741.